कृपया अन्य खोज का प्रयास करें
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Sandeep Laumas | 54 | 2018 | Independent Director |
John L. Ryan | 80 | 2018 | Independent Director |
Shalabh K. Gupta | 50 | 2016 | Founder, Chairman, CEO & President |
Ravindra L. Mehta | - | - | Member of Scientific Advisory Board |
Pablo E. Pergola | - | - | Member of Scientific Advisory Board |
Myles Selig Wolf | 52 | - | Member of Scientific Advisory Board |
Gaurav Aggarwal | 51 | 2023 | Independent Director |
Glenn Matthew Chertow | - | - | Member of Scientific Advisory Board |
Saraswati Kenkare-Mitra | 56 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है